6-氯-2-甲基-4-苯基-ALPHA-丙基-3-喹啉乙酸 | 957890-42-5

• 物质功能分类: 生物化工 - 生化试剂 - 激动剂抑制剂
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 6-氯-2-甲基-4-苯基-ALPHA-丙基-3-喹啉乙酸
• 英文名称: CX05168
• 英文别名: 2-(6-Chloro-2-methyl-4-phenylquinolin-3-yl)pentanoic acid
• CAS: 957890-42-5
• 化学式: C₂₁H₂₀ClNO₂
• 分子量: 353.848
• InChiKey: XRPUJSGGRFQZPJ-UHFFFAOYSA-N

物化性质

• 沸点：
  521.5±50.0 °C(Predicted)
• 密度：
  1.228
• 溶解度：
  DMSO：≥100mg/mL（282.61mM）；水：< 0.1 mg/mL（不溶）

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  50.2
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Functional cure of retroviral infection
  申请人：KATHOLIEKE UNIVERSITEIT LEUVEN

  公开号：US10806734B2

  公开（公告）日：2020-10-20

  The application relates to methods of curing retroviral infections, i.e. ensuring remission of retroviral infections, more particularly HIV infections, by administering a compound which is capable of binding to the LEDGF/p75 binding pocket of HIV-integrase and inhibiting LEDGF/p75-IN protein-protein interaction. The application further relates to the use of LEDGINs in retroviral gene therapy.

  本申请涉及治疗逆转录病毒感染的方法，即通过施用一种能够与HIV-整合酶的LEDGF/p75结合袋结合并抑制LEDGF/p75-IN蛋白-蛋白相互作用的化合物，确保逆转录病毒感染，特别是HIV感染的缓解。该申请还涉及 LEDGINs 在逆转录病毒基因疗法中的应用。
• FUNCTIONAL CURE OF RETROVIRAL INFECTION
  申请人：Katholieke Universiteit Leuven

  公开号：EP3294277A1

  公开（公告）日：2018-03-21
• Novel Control Switch
  申请人：GlaxoSmithKline Intellectual Property Development Limited

  公开号：US20220323494A1

  公开（公告）日：2022-10-13

  The invention relates to a chimeric antigen receptor (CAR) suitable for the treatment of human subjects, comprising: (i) a signalling chain comprising a transmembrane domain and a signalling domain; (ii) a non-signalling chain comprising a target binding domain and a transmembrane domain; wherein, one of said chains further comprises a HIV Integrase catalytic core domain (CCD) or a functional fragment or variant thereof, and the other chain further comprises a LEDGF/p75 integrase binding domain (IBD), or a functional fragment or variant thereof.
• [EN] COMPOUNDS FOR TREATMENT OF FELINE LEUKEMIA IN FELIDAE<br/>[FR] COMPOSÉS DESTINÉS AU TRAITEMENT DE LA LEUCÉMIE FÉLINE CHEZ LES FÉLIDÉS
  申请人：UNIV ZUERICH

  公开号：WO2012095388A2

  公开（公告）日：2012-07-19

  The invention provides for inhibitors of HIV integrase, particularly raltegravir, for the treatment of FeLV in felidae, particularly in house cats.
• [EN] FUNCTIONAL CURE OF RETROVIRAL INFECTION<br/>[FR] TRAITEMENT FONCTIONNEL D'UNE INFECTION RÉTROVIRALE
  申请人：UNIV LEUVEN KATH

  公开号：WO2016180770A1

  公开（公告）日：2016-11-17

  The application relates to methods of curing retroviral infections, i.e. ensuring remission of retroviral infections, more particularly HIV infections, by administering a compound which is capable of binding to the LEDGF/p75 binding pocket of HIV-integrase and inhibiting LEDGF/p75-IN protein-protein interaction. The application further relates to the use of LEDGINs in retroviral gene therapy.